ImmunoGen, Inc. (IMGN)
(Delayed Data from NSDQ)
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[IMGN]
Reports for Purchase
Showing records 121 - 140 ( 282 total )
Industry: Medical - Drugs
A Compelling Regulatory Advance We Did Not Anticipate; Target Raised to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Industry: Medical - Drugs
Activity and TEAE Profile Imply Continued Evaluation Both as a Monotherapy and in Combination
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
IMGN632 at the ASH; Activity Supported by an Adequate Tolerability
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
If It AIn''t Broke, Don''t Fix It: MIRASOL Teed-up to Unwind the FORWARD I Misstep
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Model Updated to Reflect Impact of Restructuring; Target Goes to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Looking Back at 1H19 With an Eye Towards Fulfilling Mirvetuximab''s Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Industry: Medical - Drugs
Industry: Medical - Drugs
Model Update Post Telegraphed Restructuring; $240M Pro Forma Cash Good Through 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Industry: Medical - Drugs
Industry: Medical - Drugs
Avastin Plus Mirvetuximab Might Be More Encompassing Than Mirvetuximab Monotherapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Industry: Medical - Drugs
Another Look at Avastin + Mirvetuximab; Move Into Earlier Lines of Therapy a Clear Option, Balance Sheet Permitting
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D